In a recently released report regarding the rising costs of cancer therapies, a presidential panel notes progress in tackling cancer through targeted drugs and immunotherapies but says their accessibility to the public is limited due to prices that are rising dramatically. The President’s Cancer Panel has recommended aligning drug prices with their value to patients, providing affordable access to the appropriate cancer drugs for all patients, and more investments in biomedical research to drive future innovation.
The report titled “Promoting Value, Affordability and Innovation in Cancer Drug Treatment” also urges all stakeholders—drug developers and manufacturers, policymakers, government, public and private payers, healthcare institutions and systems, providers, and patients—to work together to address rising costs and ensure that patients have access to innovative, high-value, and affordable cancer drugs.
The American Society of Clinical Oncology applauded the panel for “calling for urgent collaborative action to align cancer drug prices with value." The American Cancer Society Cancer Action Network (ACSCAN) said the report is a “starting point for a critical national conversation” on drug pricing. “If patients are going to maintain access to the drugs they need, there has to be a balanced approach that recognizes the need for innovation and affordability,” said Kristen Sloan, vice president for public policy, ACSCAN.
To read the full report, click here.